Program EADA 2021

The program on 18 November consists of 3 building blocks. Registration for lectures in one or more of the various blocks is now open:

I: Setting the scene: Corporates, Authorities & globally active Organisations

II: Technology and Product Updates in AMR: Academia, Start-ups & SMEs

III: Accelerating AMR R&D: Initiatives to boost national / global AMR R&D

CETI: SETTING THE SCENE OF AMR R&D
09:30
_____
Antimicrobial resistance (AMR): global threat and innovative solutions
Dr Maarten van Dongen; AMR Insights (Netherlands)
10:00
_____
Global coordination of R&D and priority settings to fight AMR
Dr Valeria Gigante; World Health Organisation (CH)
10:20
_____
iiCON: Delivering Solutions for Integrated Solutions in AMR
Prof Janet Hemingway; Liverpool School of Tropical Medicine (UK)
10:40
_____
– Coffee break –
11:00
_____
JPIAMR: Global collaborative platform supporting transnational research
Dr Shawon Lahiri; JPIAMR (Sweden/EU)
11:20
_____
Fighting antibiotic resistance, today and tomorrow
Dr Colin Garner; Antibiotic Research UK (UK)
11:40
_____
Alternative approaches to antibiotics in fighting AMR
Dr Maneesh Paul; Acharya Institutes (India)
12:00
_____
New antibiotics to patients by 2030: partnering to create market conditions that enable sustainable investment in the antibiotic pipeline
Dr Martin Heidecker; AMR action fund
12:20
_____
Concluding remarks on the morning program
Dr Maarten van Dongen; AMR Insights (Netherlands)
12:35
_____
– Lunch break –
II: TECHNOLOGY AND PRODUCT UPDATES IN AMR
01:00
_____
Novel LpxA inhibitors targeting Pseudomonas aeruginosa
Dr Alastair Parkes; Evotec (UK)
01:20
_____
Next Generation Anti-Infectives To Fight Global Anti-Microbial Resistance
Leonie de Best; Madam Therapeutics (Netherlands)
01:40
_____
Two exciting late stage clinical assets and a range of earlier research programmes
Dr Bill Love; Destiny Pharma (UK)
02:00
_____
Tears hold a possibility to fight ABR
Dr Richard Stead; Qures Goup (UK)
02:20
_____
A rapid, low cost, antibiotic susceptibility test for urinary tract infections
Dr Stuart Hannah; University of Strathclyde/ Microplate Dx (UK)
02:40
_____
Novel non-pharmaceutical approach to prevent and control of bacterial infections without giving rise to AMR
Dr Vipula Tailor: Sonix Medical Devices, Inc (USA)
03:00
_____
Reconsidering current academic approaches in antibiotics medicinal chemistry, cases studies
Dr Yves Janin; CNRS-Institut Pasteur (France)
03:20
_____
Predicting antimicrobial susceptibility directly from blood using whole-genome sequencing
Dr Melis Anahtar, MD; Day Zero Diagnostics (USA)
03:40
_____
Fighting MDR Neisseria gonorrhoeae with novel massive polypharmacology
Dr Pascal Mayer: Alphanosos (France)
03:50
_____
– Coffee break –
III: ACCELERATING AMR R&D
04:00
_____
Supporting innovators to fight drug-resistant bacterial infections
Douglas Haggstrom; INCATE (Switzerland)
04:20
_____
Global AMR R&D Hub: Catalysing the transition from evidence to global AMR policy decisions
Dr Satya Dash; Global AMR R&D Hub (Germany)
04:40
_____
Creating a large collection of chemical matter specifically targeting Gram-negative antimicrobial drug discovery
Dr Bruce Blough; CC4CARB / NIH NIAID (USA)
05:00
_____
Delivering drug and/or diagnostic in the areas of Neglected Diseases
Dr Shridhar Narayanan; Foundation for Neglected Disease Research (India)
05:10
_____
Fostering AMR R&D in India, for India and beyond
Dr Taslimarif Saiyed; C-CAMP (India)
05:20
_____
The role of Diagnostics in the fight against AMR, the LMICs perspective
Dr Cecilia Ferreyra; FIND (Switzerland )
05:40
_____
ILSE: a unique model to accelerate early innovation in AMR
Dr Thomas Richardson, ILSE (USA)
05:50
_____
Closing remarks
Dr Maarten van Dongen; AMR Insights (Netherlands)
06:00
_____
– Closure –
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!